Although CHOP remains the standard front-line therapy for PTCL, given these poor outcomes, most PTCL patients (with the exception of ALK-positive ALCL) should be considered for clinical trials of initial therapy. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.